Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.66
-5.45 (-2.59%)
AAPL  266.78
+2.20 (0.83%)
AMD  194.94
-5.21 (-2.60%)
BAC  51.37
-1.70 (-3.19%)
GOOG  310.97
-3.93 (-1.25%)
META  639.02
-16.63 (-2.54%)
MSFT  384.49
-12.74 (-3.21%)
NVDA  190.47
+0.66 (0.35%)
ORCL  139.65
-8.43 (-5.69%)
TSLA  394.77
-17.05 (-4.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.